



# Kent Academic Repository

**Banerji, Udai, Dean, Emma J., Pérez-Fidalgo, J. Alejandro, Batist, Gerald, Bedard, Philippe L., You, Benoit, Westin, Shannon N., Kabos, Peter, Garrett, Michelle D., Tall, Mathew and others (2018) *A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.* Clinical Cancer Research, 24 (9). pp. 2050-2059. ISSN 1078-0432.**

## Downloaded from

<https://kar.kent.ac.uk/63859/> The University of Kent's Academic Repository KAR

## The version of record is available from

<https://doi.org/10.1158/1078-0432.CCR-17-2260>

## This document version

Author's Accepted Manuscript

## DOI for this version

## Licence for this version

UNSPECIFIED

## Additional information

## Versions of research works

### Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

### Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

## Enquiries

If you have questions about this document contact [ResearchSupport@kent.ac.uk](mailto:ResearchSupport@kent.ac.uk). Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

**A Phase 1 open-label study to identify a dosing regimen of the  
pan-AKT inhibitor AZD5363 for evaluation in solid tumors and  
in *PIK3CA*-mutated breast and gynecologic cancers**

Udai Banerji,<sup>1</sup> Emma J. Dean,<sup>2</sup> J. Alejandro Pérez-Fidalgo,<sup>3</sup> Gerald Batist,<sup>4</sup> Philippe L. Bedard,<sup>5</sup> Benoit You,<sup>6</sup> Shannon N. Westin,<sup>7</sup> Peter Kabos,<sup>8</sup> Michelle D. Garrett,<sup>9</sup> Mathew Tall,<sup>10</sup> Helen Ambrose,<sup>11</sup> J. Carl Barrett,<sup>12</sup> T. Hedley Carr,<sup>11</sup> S.Y. Amy Cheung,<sup>11</sup> Claire Corcoran,<sup>11</sup> Marie Cullberg,<sup>11</sup> Barry R. Davies,<sup>11</sup> Elza C. de Bruin,<sup>11</sup> Paul Elvin,<sup>11</sup> Andrew Foxley,<sup>11</sup> Peter Lawrence,<sup>11</sup> Justin P.O. Lindemann,<sup>11</sup> Rhiannon Maudsley,<sup>11</sup> Martin Pass,<sup>11</sup> Vicky Rowlands,<sup>11</sup> Paul Rugman,<sup>11</sup> Gaia Schiavon,<sup>11</sup> James Yates,<sup>11</sup> Jan H.M. Schellens<sup>13</sup>

<sup>1</sup>Clinical Pharmacology and Trials, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; <sup>2</sup>Medical Oncology (Drug Development), University of Manchester and The Christie NHS Foundation Trust, Manchester, UK; <sup>3</sup>Department of Oncology and Hematology, INCLIVA Biomedical Research Institute, Hospital Clínico Universitario de Valencia, CIBERONC, Valencia, Spain; <sup>4</sup>Department of Oncology, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada; <sup>5</sup>Department of Medical Oncology, The Princess Margaret Cancer Centre, Toronto, Canada; <sup>6</sup>Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; <sup>7</sup>Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; <sup>8</sup>Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA; <sup>9</sup>School of Biosciences, University of Kent, Canterbury, UK; <sup>10</sup>Clinical PD Biomarker Group, The Institute of Cancer Research, Sutton, UK; <sup>11</sup>IMED, AstraZeneca, Cambridge, UK; <sup>12</sup>IMED, AstraZeneca, Massachusetts, USA; <sup>13</sup>Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, and

Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

This study (Study 1, AstraZeneca study D3610C00001; NCT01226316) was presented in part at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) (abstract number 2541) and at the 2015 ASCO Meeting (abstract number 2500).

**Running title:** AZD5363 in solid and *PIK3CA*-mutated cancers

**Abbreviations:** 2/7, 2 days per week; 4/7, 4 days per week; AE, adverse event; AUC, area under the plasma concentration–time curve; bid, twice daily; C, cycle; C<sub>b</sub>, *PIK3CA*-mutant breast cancer; C<sub>g</sub>, *PIK3CA*-mutant gynecologic cancer; C<sub>max</sub>, maximum plasma concentration; C<sub>min</sub>, minimum plasma concentration; cont, continuous; CTCAE, Common Terminology Criteria for Adverse Events; ctDNA, circulating free DNA; D, day; DLT, dose-limiting toxicity; ECG, electrocardiogram; ER+, estrogen receptor positive; HER2+, human epidermal growth factor receptor positive; Int, intermittent; IQR, interquartile range; MTD, maximum tolerated dose; NA, not available; PD, pharmacodynamics; PI3K, phosphatidylinositol-3-kinase; PK, pharmacokinetics; PoM, proof of mechanism; PRP, platelet-rich plasma; RECIST, Response Evaluation Criteria in Solid Tumours; SD, standard deviation; SRC, Safety Review Committee; t<sub>1/2</sub>, half-life; t<sub>max</sub>, time to maximum plasma concentration

**Financial support:** This study (Study 1; NCT01226316) was sponsored by AstraZeneca.

**Corresponding author:**

Dr Udai Banerji

The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust

Downs Road

Sutton

SM2 5PT

United Kingdom

Email: [udai.Banerji@icr.ac.uk](mailto:udai.Banerji@icr.ac.uk)

Phone: 020-8661-3984

Fax: 020-8642-7979

**Keywords:** AZD5363, AKT, *PIK3CA*, cancer, Phase 1

**Word count:** 3656 (5000 max)

**Number of tables/figures:** 2/4 (6 max)

**References:** 29 (50 max)

## **Abstract (249/250 max)**

**Purpose:** This Phase 1, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives were to investigate the safety, tolerability and pharmacokinetics of AZD5363, define a recommended dosing schedule, and evaluate preliminary clinical activity.

**Experimental design:** Patients were aged  $\geq 18$  years with WHO performance status 0–1. Dose escalation was conducted within separate continuous and intermittent (4 days/week [4/7] or 2 days/week [2/7]) schedules with safety, pharmacokinetic and pharmacodynamic analyses. Expansion cohorts of approximately 20 patients each explored AZD5363 activity in *PIK3CA*-mutant breast and gynecologic cancers.

**Results:** Maximum tolerated doses were 320 mg, 480 mg and 640 mg for continuous (n=47), 4/7 (n=21) and 2/7 (n=22) schedules, respectively. Dose-limiting toxicities were rash and diarrhea for continuous, hyperglycemia for 2/7, and none for 4/7. Common adverse events were diarrhea (78%) and nausea (49%) and, for CTCAE grade  $\geq 3$  events, hyperglycemia (20%). The recommended Phase 2 dose (480 mg bid, 4/7 intermittent) was assessed in *PIK3CA*-mutant breast and gynecologic expansion cohorts: 46% and 56% of patients, respectively, showed a reduction in tumor size, with RECIST responses of 4% and 8%. These responses were less than the pre-specified 20% response rate; therefore, the criteria to stop further recruitment to the *PIK3CA* cohort were met.

**Conclusions:** At the recommended Phase 2 dose, AZD5363 was well tolerated and achieved plasma levels and robust target modulation in tumors. Proof-of-concept

responses were observed in patients with *PIK3CA*-mutant cancers treated with AZD5363.

## **Statement of translational relevance (144/150 max)**

AZD5363 is a potent, selective inhibitor of AKT, a key node in the PI3K/AKT/mTOR pathway that is activated in a wide range of malignancies. *In vivo*, AZD5363 inhibited tumor growth in xenograft models. Preclinically, sensitivity to AZD5363 has been strongly related to the presence of *PIK3CA* mutations, which are relatively common in breast and gynecologic cancers. Our study, the first-in-human study of AZD5363, showed that at an identified recommended Phase 2 dose, AZD5363 was well tolerated and achieved plasma levels and robust target modulation in tumors. The study is also the first report of a biomarker-stratified cohort (*PIK3CA* mutations in breast and gynecologic cancers) of patients treated with an AKT inhibitor. Results suggest that future efforts in developing this class of drugs for the treatment of solid tumors, including *PIK3CA*-mutated breast and gynecologic cancers, will need to be in combination with other anticancer drugs.

## Introduction

AKT is a serine/threonine protein kinase that functions as a key node in the phosphatidylinositol-3-kinase (PI3K)/AKT network (also known as the PI3K/AKT/mTOR pathway), with a fundamental role in cell survival and proliferation (1). AKT is over-expressed or activated in a wide range of solid and hematologic malignancies, and aberrant AKT signaling is also associated with resistance to established cancer therapies, as well as advanced disease and/or poor prognosis (2).

AZD5363 is a potent, selective inhibitor of the kinase activity of all three AKT isoforms (AKT1, -2, and -3) (3). *In vitro*, AZD5363 inhibited tumor cell proliferation and phosphorylation of the AKT substrates PRAS40 and GSK3 $\beta$ , as well as the downstream pathway protein S6. *In vivo*, AZD5363 inhibited tumor growth in xenograft models and remained pharmacodynamically active for at least 24 hours (3). Preclinically, sensitivity to AZD5363 has been strongly related to the presence of *PIK3CA* mutations (4, 5), a trend that has also been observed with other inhibitors of the PI3K/AKT/mTOR pathway (6). *PIK3CA* mutations are found in breast and gynecologic cancers, and evaluation of AZD5363 in these settings is warranted (1).

We report the first-in-human study of AZD5363, which evaluated safety, pharmacokinetics (PK), and pharmacodynamics (PD) in three schedules and recommended a Phase 2 dose for future development. We also report the first evaluation of an AKT inhibitor used as a single agent in a *PIK3CA*-mutated breast and ovarian cancer population.



## **Materials and methods**

### **Study design**

This is a multipart, Phase 1, open-label, multicenter study of oral AZD5363 in patients with advanced solid malignancies (Study 1; NCT01226316; Supplementary Figure 1). Parts A and B were, respectively, the dose-escalation and -expansion phase. Part C focused on an expansion cohort of patients with a *PIK3CA* tumor mutation. An additional expansion cohort of patients with an *AKT1* tumor mutation (Part D) will be reported separately.

### **Patients**

All patients were aged  $\geq 18$  years with a WHO performance status of 0–1 and minimum life expectancy of 12 weeks. Patients in Part C had advanced estrogen receptor positive (ER+) or human epidermal growth factor receptor 2 positive (HER2+) breast cancer (based on local testing) (7) or gynecologic (ovarian, cervical, or endometrial) cancer, with any *PIK3CA* mutation detected by local or central testing, and at least one measurable lesion. Additionally for Part C, where known, other solid tumors (ie not breast or gynecologic) should be negative for mutations of *KRAS*, *NRAS*, *HRAS*, and *BRAF*. Key exclusion criteria are summarized in the supplementary material.

### **Study objectives**

The primary objective of Parts A and B was to investigate the safety and tolerability of oral AZD5363 and to define a recommended monotherapy dose and schedule for further clinical evaluation. Secondary objectives included PK evaluation of AZD5363 and preliminary assessment of antitumor activity. The objectives of Part C were to investigate safety, tolerability, PK, and antitumor activity of the defined AZD5363 dosing schedule in patients with ER+ or HER2+ breast cancer or gynecologic cancer harboring a *PIK3CA*

mutation. Exploratory objectives of Study 1 overall included the characterization of the PD effects of AZD5363 in paired tumor biopsies and in platelet-rich plasma (PRP; Parts A and B).

### **Study design and treatment**

#### *Part A – dose escalation*

Cohorts of 3–6 unselected patients received a single starting dose of 80 mg of AZD5363 and, after a 3- to 7-day washout, AZD5363 twice daily (bid). The dosing cycle was 21 days, excluding the run-in dose. Upon reaching a continuous dose considered appropriate by the Safety Review Committee (SRC), two intermittent dosing schedules were initiated in parallel: 4 days on, 3 days off every week (4/7) and 2 days on, 5 days off every week (2/7). Dose escalation continued for each schedule until a non-tolerated dose was attained ( $\geq 2/6$  dose-limiting toxicities [DLTs]) and a maximum tolerated dose (MTD) was identified. Definitions of DLTs are provided in the supplementary material.

#### *Part B – dose expansion*

To confirm selection of the recommended dose for the schedules explored in Part A, the safety profile and tolerability were evaluated in up to nine additional unselected patients. The SRC also reviewed safety and tolerability data on an ongoing basis.

#### *Part C – expansion in PIK3CA-mutant patients*

Two cohorts of patients with *PIK3CA*-mutant ER+ or HER2+ breast cancers (Cb cohort) or gynecologic cancers (Cg cohort) received the recommended dose and schedule identified from Parts A and B. Each cohort permitted a maximum of 120 patients; recruitment to each cohort was prospectively contingent on positive interim efficacy and

safety data reviews after 20 and 40 patients had the opportunity to be followed for  $\geq 12$  weeks.

The trial (Study 1; NCT01226316) was performed in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice, and the AstraZeneca policy on bioethics (8). The local ethics committee or independent review board at each investigator site approved the protocol prior to study commencement. All patients provided written informed consent prior to study participation.

### **Assessments**

Safety and tolerability were assessed by continual monitoring of adverse events (AEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Serial venous blood samples for PK assessment of AZD5363 in plasma were taken up to 48 hours post-dose in Part A, and up to 1 week after the last day of weekly dosing in Part B. Evaluated PK parameters included area under the plasma concentration–time curve (AUC), maximum plasma concentration ( $C_{max}$ ), time to  $C_{max}$  ( $t_{max}$ ), and apparent terminal half-life ( $t_{1/2}$ ).

Blood samples were obtained at scheduled time points to assess changes in PD biomarkers of AKT inhibition (such as p-GSK3 $\beta$  and pPRAS40) in PRP using solid-phase enzyme-linked immunosorbent Mesoscale Discovery multiplex assays. Paired tumor biopsies (pre- and on treatment) from consenting patients participating in this study and in a study of AZD5363 in Japanese patients (Study 4; NCT01353781) (9) were pooled. Pooling provided an adequately sized cohort to assess proof of mechanism (PoM) for the measurement of changes in AKT pathway effectors, including p-AKT, p-PRAS40, p-GSK3 $\beta$ , and Foxo3a/Foxo1 localization, by immunohistochemistry

(10). Details on the collection and analysis of PRP and tumor tissue samples, and mutation analyses in tissue and circulating free DNA (ctDNA), are described in the supplementary material.

To determine antitumor activity, tumor assessments were categorized based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Percentage change in tumor size was determined at each visit by the percentage change in the sum of the diameters of target lesions compared with baseline.

### **Statistical methods**

All patients who received  $\geq 1$  dose of AZD5363 were included in the safety analyses. Safety and tolerability were assessed in terms of AEs, serious AEs, deaths, laboratory data, vital signs, electrocardiogram (ECG) changes, left ventricular ejection fraction, and abnormalities of glucose metabolism. All patients who provided appropriate samples were assessed for PK and PD. Standard non-compartmental PK parameters were calculated using Phoenix™ WinNonlin® version 6 software. Modeling and simulation were applied to emerging safety, PK, and PD data to provide an understanding of any dose exposure–response relationships, and to support dose-escalation and dosing-schedule decisions. Preclinical PK, PD, and efficacy data were used to define PoM thresholds for the reduction of phosphorylation of GSK3 $\beta$  and PRAS40 to provide confidence that on-target PoM was achieved at tolerable doses (described in the supplementary material).

The pre-defined formal trigger in Part C to stop the study for futility was four or fewer responses by RECIST once 20 patients in each cohort had the opportunity to be followed for 12 weeks, ie a  $\leq 10\%$  chance that the true proportion of RECIST responses

was  $\geq 40\%$ . Antitumor activity was assessed by response rate, with two-sided Clopper–Pearson confidence intervals to provide probability statements of the efficacy signal.

### **Role of the funding source**

This study was sponsored by AstraZeneca. The study funder, AstraZeneca, provided organizational support, obtained data, did the analyses, and had a role in data interpretation and writing of the manuscript. All authors had access to study data. The corresponding author (UB) had unrestricted access to all study data and had final responsibility for the decision to submit for publication.

## Results

### Dose escalation and expansion (Parts A and B)

#### *Patients*

A total of 90 patients were assigned to treatment; 47, 21, and 22 received AZD5363 in the continuous, 4/7, and 2/7 intermittent schedules, respectively. Patient demographic and baseline clinical characteristics are shown in Table 1. The most common cancers were rectal/colorectal (29%). By the time of the final analysis, all 90 patients had ceased study medication, most commonly for progression of the disease under investigation (64%).

#### *Safety and tolerability*

The MTDs of the continuous, 4/7, and 2/7 schedules were 320, 480, and 640 mg bid, respectively (Supplementary Figure 2). For the continuous dosing schedule, the 600 mg bid cohort was not tolerated: 2/2 patients experienced DLTs (one event of grade 3 rash and one of grade 4 rash). An intermediate dose level of 480 mg bid was, therefore, investigated; in this cohort, 4/6 patients experienced DLTs (three events of grade 3 rash and one of grade 3 diarrhea). At a further lower dose level of 320 mg bid, 0/12 patients experienced DLTs, and this dose was considered the MTD for the continuous schedule. In the 4/7 intermittent dosing schedule, no DLTs were observed in the 480 mg bid (n=11) and 640 mg bid (n=10) cohorts; however, based on the presence of chronic toxicities such as rash and diarrhea observed outside the first 21-day cycle DLT window, the lower dose of 480 mg bid was considered tolerable and appropriate for chronic use with 4/7 dosing. In the 2/7 intermittent dosing schedule, at 800 mg bid, 3/14 patients had DLTs (two events of grade 4 hyperglycemia and one of grade 3 hyperglycemia); again, considering observed chronic toxicities, a dose of 640 mg bid was explored. In this cohort, DLTs were observed in 1/8 patients (one event of grade 4 hyperglycemia), and

the 640 mg bid dose was considered tolerable (Supplementary Figure 2). All DLTs were reversible; no events of ketoacidosis were reported in patients with hyperglycemia. Two patients remained on AZD5363 for longer than 6 months (one patient on the 480 mg bid 4/7 schedule and one patient on the 800 mg bid 2/7 schedule); the median duration of exposure was 44 days (range 1–507).

The most frequently reported AEs across all dosing schedules were gastrointestinal events (diarrhea, vomiting, nausea) (Table 2). Grade  $\geq 3$  AEs were experienced by 56 patients (62%), most commonly hyperglycemia (n=18; 20%), diarrhea (n=13; 14%) and maculopapular rash (n=10; 11%) (Supplementary Table 5). Overall, 21 patients (23%) had an AE leading to discontinuation; the most common ( $\geq 2\%$ ) were diarrhea (8%), maculopapular rash (8%), and dehydration (2%). AEs leading to dose interruption or reduction were experienced by 29 (32%) and 21 (23%) patients, respectively. No AEs resulted in death, and seven patients died as a result of the disease under investigation. All 90 patients had blood glucose levels above the upper limit of normal at some point following initiation of therapy with AZD5363 – this developed within the first 2 weeks of multiple dosing in the majority of patients (77%). Grade 3 elevations ( $>13.9$  mmol/L) were seen in 33 patients (37%). No other clinically important trends were observed in laboratory parameters, vital signs, physical findings, or ECG changes.

#### *Pharmacokinetics and pharmacodynamics*

Plasma concentrations of AZD5363 showed a median  $t_{\max}$  of 2 hours (range 0.5–6), with a terminal half-life of approximately 10 hours (range 7–15) after the first dose. Exposure was approximately dose proportional for doses of 80–800 mg (Figure 1A). Multiple-dose PK profiles are shown in Figure 1B. The geometric mean PK exposures on Day 4 of the 480 mg dose in the 4/7 schedule were:  $C_{\max}$  1426 ng/mL; minimum plasma

concentration ( $C_{\min}$ ) 357 ng/mL; and AUC 7952 ng·h/mL. Intermittent dose schedules exceeded the predicted efficacious  $C_{\min}$  estimated from xenograft tumors (supplementary material) (11). The mean fraction of the AZD5363 dose excreted unchanged in urine ranged from 4% to 7%. Changes in PRAS40 and GSK3 $\beta$  phosphorylation in PRP occurred across multiple dose levels and precluded any definitive conclusion regarding a dose–response relationship. In patients treated with the recommended Phase 2 dose and schedule (480 mg bid, 4/7 intermittent), a reduction of >30% in pPRAS40 and pGSK3 $\beta$  compared with baseline at 4 hours after the single dose of AZD5363 was observed (Figure 2A), with return to baseline levels approximately 10 hours post-treatment (Figure 2B).

Additional observations indicating PD activity of AZD5363 included an increase in plasma and blood glucose, insulin, and C-peptide levels. In particular, blood glucose levels increased across all cohorts and peaked approximately 4 hours after each dose (Supplementary Figure 5), returning towards pre-dose baseline levels 8 hours post-dose, with a clear dose–response relationship in terms of the magnitude of peak glucose levels observed (not shown).

#### *Proof of target engagement in tumor tissue*

Evaluable paired tumor biopsies from 12 patients (nine from the current study [Study 1; NCT01226316] and three from Study 4 (AstraZeneca study D3610C00004) [NCT01353781]) (9) who received a range of doses and schedules were evaluated to assess PoM. Over 50% inhibition of pPRAS40 was seen in 4/12 paired biopsies and >30% decrease in pGSK3 $\beta$  was observed in 6/11 paired biopsies; 4/11 samples met both endpoints (Figure 3A and 3B, Supplementary Table 1). Downregulation of PD biomarkers was observed >4 hours post-dose, including with intermittent dosing



(Supplementary Table 1). These data are consistent with the PD response achieved in BT474c xenografts grown in nude mice at a dose that resulted in significant tumor growth inhibition (Supplementary Figure 4). AZD5363 treatment also increased phosphorylation levels of AKT (consistent with ATP competitive mechanism of action), inhibited phosphorylation of 4EBP1, and resulted in inhibition of Foxo nuclear translocation (Figure 3A) (10). In the five patients treated with the recommended Phase 2 dose and schedule (480 mg bid, 4/7 intermittent), the average percentage decrease from baseline for pPRAS40 (59%) and pGSK3b (67%) exceeded the PD response required for preclinical efficacy (Figure 3B).

#### *Recommended Phase 2 dose*

Based on preclinical models, the trough plasma concentrations achieved at the tolerable dose of 320 mg bid on a continuous schedule exceeded those required for xenograft activity (Supplementary Figure 4). Further modeling has suggested that a 1.3- and 1.7-fold dose level over continuous dosing would be efficacious when administered on the 4/7 and 2/7 schedules, respectively (11). Based on the combination of tolerability profile, PK profile achieved, evidence of target engagement in normal and tumor tissue, and modeling predictions of efficacy, the dose of 480 mg bid on a 4/7 intermittent schedule was declared as the recommended Phase 2 dose. The dose level of 640 mg bid 2/7 was also tolerable, achieved adequate PK exposure, showed evidence of target modulation in PRP (tumor biopsy data were not available in this schedule), and was predicted to be efficacious from modeling of preclinical data. This schedule could be of use in combination studies in the future.

### *Antitumor activity*

There was limited evidence that AZD5363 induced tumor shrinkage in the unselected patient population in Parts A and B. A total of 27 (30%) and six (7%) patients achieved stable disease for  $\geq 6$  and  $\geq 12$  weeks, respectively. A *PIK3CA* mutation was detected in 12/67 patients with archival tumor tissue suitable for exploratory Sequenom™ analysis, of whom 8/12 received an AZD5363 dose  $\geq 400$  mg. Additionally, 0/68 tumors harbored an *AKT1* E17K mutation, 29% (20/68) harbored a *RAS* mutation (18 *KRAS* and 2 *NRAS*), and 25% (3/12) of the *PIK3CA*-mutant tumors had concurrent *KRAS* mutation (Figure 4A). In particular, the patient who achieved a RECIST partial response (*PIK3CA* E545K mutant) had cervical cancer with hepatic and lymph node metastases and was treated with 400 mg bid continuously.

### **Patients with tumors harboring mutations in *PIK3CA* (Part C)**

At the final analysis, 31 patients with *PIK3CA*-mutant breast cancer (Cb cohort) and 28 patients with *PIK3CA*-mutant gynecologic cancer (Cg cohort) had received AZD5363, of whom 54 were included in the main tumor response analysis set. Of patients included in the analysis set (excluding 3 patients with no evaluable follow-up assessments), 12/26 (46%) and 14/25 (56%) showed a reduction in size of their tumors in the Cb and Cg cohorts, respectively (Figure 4B). The corresponding confirmed RECIST responses at final analysis were 1/28 (4%) and 2/26 (8%), respectively. The observations at the interim assessment (scheduled when 20 patients had been dosed and had the opportunity to reach 12 weeks of treatment for each cohort) showed a RECIST response rate of  $\leq 20\%$  for a single agent and therefore met the criteria to stop further recruitment. Results of *PIK3CA* mutational analysis in tissue and ctDNA and other exploratory biomarkers (eg PTEN status, *ESR1* mutation status) are shown in Figure 4A and Supplementary Table 4 and described in detail in the supplementary material.

The safety profile of AZD5363 in Part C, which is described in detail in the supplementary material, was consistent with the findings in Parts A and B.

## Discussion

This first-in-human study assessed the safety and tolerability of AZD5363 and identified a recommended dosing schedule for further clinical evaluation. The study also explored single-agent activity of AZD5363 in populations of patients who had metastatic breast and gynecologic cancers with *PIK3CA* mutations.

DLTs of AZD5363 in the dose-escalation part of our study (Part A) were skin rash, diarrhea, and hyperglycemia. Whereas skin rash and diarrhea were predominant in the continuous schedule, hyperglycemia associated with the period of  $C_{max}$  was predominant in the intermittent 2/7 schedule, where highest AZD5363 exposures were achieved. The cases of skin rash and diarrhea were self-limiting and recovered once treatment stopped. These AEs have been noted in Phase 1 studies of other AKT inhibitors, such as the allosteric inhibitor MK2206 or kinase inhibitors such as GSK2141795 and ipatasertib (GDC-0068) (1, 12-17). Hyperglycemia development was acute and indicative of the inhibitory effect of AZD5363 on AKT, a key regulator of glucose transport and metabolism in peripheral tissues and the liver (17). No patients had ketotic or non-ketotic hyperosmolar coma. However, patients with diabetes were excluded from our study and it is not possible to rule out these complications in a diabetic population. A number of patients with hyperglycemia were treated with metformin according to a protocol-defined algorithm; however, the efficacy of this intervention requires further study.

The trough concentrations predicted to provide efficacy based on preclinical modeling were exceeded in patients receiving intermittent schedules. PD analyses in PRP showed levels of target inhibition that were consistent with PoM in pre- and post-biopsies from 12 patients. Owing to the limited sample size, no formal statistical testing relating to the PD

changes in tumor tissue was done. Collectively, the toxicity, PK, and PD data, critical aspects of the pharmacologic audit trail (18), have been used to select the dose of 480 mg bid intermittent 4/7 for Part C expansion and as the recommended Phase 2 dose and schedule of AZD5363 monotherapy.

Proof-of-principle responses were observed in the dose-escalation phase of our study (eg *PIK3CA* E545K mutant cervical cancer). Within the *PIK3CA* expansion cohorts, a number of patients showed regression of their tumors (46% in breast cancer and 56% in gynecologic cancers; Figure 4B). However, the RECIST response rates in the two expansion cohorts of patients with *PIK3CA* mutations in ER+ breast cancer and gynecologic cancers were modest (4% and 8%, respectively). Several considerations should be made. *PIK3CA* mutational status can ‘change’ upon disease recurrence (supplementary material and Supplementary Figure 3), reflecting intra-tumoral heterogeneity and clonal selection (19, 20), and studies on the role of *PIK3CA* as a predictive biomarker of PI3K pathway inhibitors have not been conclusive (21). Molecular analyses using different platforms revealed interesting differences of *PIK3CA* mutations seen in the archival tumor tissue and ctDNA at baseline. Results have been detailed in the supplementary material and Supplementary Table 4. To our knowledge, this is the first report of the evaluation of an AKT inhibitor in dedicated *PIK3CA*-mutation-positive breast and gynecologic cancers as a single agent. For example, *PIK3CA* mutations were not a requirement while evaluating the AKT inhibitor perifosine, which underwent Phase 2 trials in breast cancer and showed 0/18 responses (22), or the allosteric AKT MK2206 in breast cancer (1/20 responses) (23) and endometrial cancer (0/18 responses) (24). More recently, the Phase 1 trial of ipatasertib in solid tumors reported no RECIST responses, although there were minor degrees of tumor regression (16), and no trials evaluating the drug as a single agent in breast or gynecologic cancers

are reported. Encouraging early response rates of the use of AZD5363 (6/21, 28%) with the schedules recommended in this study have been reported (25). Further efforts to improve outcomes by combining AZD5363 with fulvestrant in *AKT*-mutant breast cancer is ongoing.

Rewiring of signal transduction pathways and clonal evolution are critical mechanisms of resistance, and combination therapy is almost inevitably necessary (26, 27). For example, the approved PI3K pathway (mTOR) inhibitor everolimus had modest clinical efficacy when used as a single agent in breast cancer (28). We consider the tumor shrinkage caused by AZD5363 as a single agent in a significant number of patients in the *PIK3CA*-mutant cohorts to be an encouraging proof of concept and the basis for evaluation of the drug in combination therapy. Our Phase 1 study has optimized multiple intermittent regimens in order to provide flexibility in the use of such a novel agent in combination with multiple standard-of-care or experimental agents (29).

Combination of AKT inhibitors with chemotherapy is hypothesized to abrogate anti-apoptotic effects of activation of AKT following treatment with chemotherapeutic agents such as cisplatin and paclitaxel. Combinations of AKT inhibitors with targeted agents include combinations with MEK inhibitors to overcome feedback signaling loops, combinations with PARP inhibitors to reduce effective homologous recombination, and combinations with hormonal agents such as fulvestrant and abiraterone in estrogen- and androgen-driven breast and prostate cancer, respectively (1).

To conclude, our research identified an optimal dose and schedule for use in subsequent multiple Phase 2 studies evaluating AZD5363, eg AZD5363 in combination with chemotherapy (NCT02423603, NCT01625286) or hormonal therapy

(NCT02077569) in breast cancer, with olaparib in ovarian cancer (NCT02338622), and with enzalutamide in prostate cancer (NCT02525068). Results of these trials are now awaited.

## **Acknowledgments**

This study (Study 1; NCT01226316) was sponsored by AstraZeneca. AZD5363 was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited). We thank James Sherwood (AstraZeneca) for performing the Sequenom analysis and acknowledge infrastructural funding from CRUK and ECMC (ICR/RMH/Christie), as well as NIHR BRC (ICR/RMH) funding, for UK sites. We thank all the investigators and site staff, with special thanks to the patients and families. Medical writing assistance was provided by Andrew Jones PhD from Mudskipper Business Ltd, funded by AstraZeneca.

## **Author contributions**

Study design: UB, EJD, HA, JCB, THC, SYAC, BRD, PL, AF, JPOL, RM, MP, PR, GS

Study oversight/conduct: SNW, HA, JCB

Literature search: UB, MC, GS

Data collection: UB, EJD, JAP-F, GB, PLB, BY, SNW, PK, MDG, MT, HA, THC, ECdB, VR, JHMS

Data analysis: UB, EJD, JAP-F, GB, PLB, BY, PK, MDG, MT, HA, THC, SYAC, ECdB, PL, RM, VR, GS, JHMS

Data interpretation: All authors

Manuscript writing: All authors

Manuscript review: All authors

Figures and tables: UB, CC, GS



## References

1. Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anti-cancer treatments. *Pharmacol Ther* 2017;172:101-15.
2. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. *Oncogene* 2005;24:7455-64.
3. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. *Mol Cancer Ther* 2012;11:873-87.
4. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. *Cancer Res* 2013;73:276-84.
5. Li J, Davies BR, Han S, Zhou M, Bai Y, Zhang J, et al. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. *J Transl Med* 2013;11:241.
6. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. *Mol Cancer Ther* 2011;10:558-65.
7. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch Pathol Lab Med* 2014;138:241-56.

8. AstraZeneca. Global Policy: Bioethics. 2015. Available at:  
<https://www.astrazeneca.com/sustainability/responsible-research.html>.
9. Tamura K, Hashimoto J, Tanabe Y, Kodaira M, Yonemori K, Seto T, et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2016;77:787-95.
10. Elvin P, Palmer A, Womack C, Tall M, Swales KE, Garrett MD, et al. Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors. *J Clin Oncol* 2014;32(15S):abst 2541.
11. Yates JW, Dudley P, Cheng J, D'Cruz C, Davies BR. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. *Cancer Chemother Pharmacol* 2015;76:343-56.
12. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. *Clin Cancer Res* 2015;21:739-48.
13. Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, et al. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. *Clin Cancer Res* 2013;19:6976-86.
14. Yan Y, Wagle M-C, Punnoose E, Musib L, Budha N, Nannini KL, et al. A first-in-human trial of GDC-0068: a novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumour tissues. *Mol Cancer Ther* 2011;10(11 Suppl):abst B154.

15. Burris HA, Siu LL, Infante JR, Wheeler JJ, Kurkjian.C., Opalinska J, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase 1 first-in-human study. *J Clin Oncol* 2011;29(suppl):abst 3003.
16. Saura C, Roda D, Rosello S, Oliveira M, Macarulla T, Perez-Fidalgo JA, et al. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. *Cancer Discov* 2017;7:102-13.
17. Hage HR, Bourron O, Hajduch E. Defect of insulin signal in peripheral tissues: Important role of ceramide. *World J Diabetes* 2014;5:244-57.
18. Banerji U, Workman P. Critical parameters in targeted drug development: the pharmacological audit trail. *Semin Oncol* 2016;43:436-45.
19. Dupont JJ, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. *Clin Cancer Res* 2011;17:667-77.
20. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. *Clin Cancer Res* 2012;18:3462-9.
21. Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. *Curr Opin Pharmacol* 2015;23:98-107.

22. Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer. *Breast Cancer Res Treat* 2008;108:87-92.
23. National Cancer Institute. Akt inhibitor MK2206 in treating patients with advanced breast cancer. 2016. Available at:  
<https://clinicaltrials.gov/ct2/show/results/NCT01277757?sect=X70156&term=nct01277757&rank=1#outcome1>.
24. Konstantinopoulos P, Makker V, Barry WT, Liu J, Horowitz NS, Birrer NJ, et al. Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. *J Clin Oncol* 2014;32(5s):abst 5515.
25. Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, et al. AKT inhibition in solid tumors with AKT1 mutations. *J Clin Oncol* 2017;doi: JCO.2017.73.0143:[Epub ahead of print].
26. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. *Nat Biotechnol* 2012;30:679-92.
27. Baselga J, Campone M, Piccart M, Burris HA, III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012;366:520-9.
28. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. *J Clin Oncol* 2009;27:4536-41.

29. Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. *Nat Rev Clin Oncol* 2016;14:57-66.

## Tables

**Table 1. Patient demographics and baseline clinical characteristics in Parts A, B, and C**

	Patients in Parts A and B (n=90)	Patients in Part C (n=59)
Mean age (SD), years	55.4 (10.8)	56.7 (12.7)
Male:female, n	51:39	2:57
Primary tumor location, n (%)		
Rectal/colorectal	26 (29)	NA
Pleura	7 (8)	NA
Lung	6 (7)	NA
Cervix	5 (6)	9 (15)
Colon	5 (6)	NA
Ovary	4 (4)	6 (10)
Breast	4 (4)	31 (53)
Uterus	0	10 (17)
Other <sup>a</sup>	33 (37)	3 (5)
WHO performance status, n (%)		
0	38 (42)	30 (51)
1	52 (58)	29 (43)
Prior anticancer regimens, n (%)		
0 regimens	0	1 (2)
1 regimen	12 (13)	6 (10)
2 regimens	27 (30)	11 (19)
≥3 regimens	51 (57)	41 (70)
Mean number of regimens (SD)	3.3 (2)	5.0 (3)

<sup>a</sup>Other includes cancers that occurred in one or two patients. NA, not available

**Table 2. Adverse events with frequency ≥15% irrespective of causality for Parts A and B in total or Part C in total**

Number (%) of patients	Parts A and B												Part C
	Schedule 1 (continuous)							Schedule 2 (4/7)		Schedule 2 (2/7)		Total (N=90)	480 mg bid; 4/7 (n=59)
	80 mg bid (n=5)	160 mg bid (n=5)	240 mg bid (n=6)	320 mg bid (n=12)	400 mg bid (n=11)	480 mg bid (n=6)	600 mg bid (n=2)	480 mg bid (n=11)	640 mg bid (n=10)	640 mg bid (n=8)	800 mg bid (n=14)		
Patients with any AE	5 (100)	5 (100)	6 (100)	12 (100)	11 (100)	6 (100)	2 (100)	11 (100)	10 (100)	8 (100)	14 (100)	90 (100)	59 (100)
Diarrhea	1 (20)	1 (20)	4 (67)	11 (92)	11 (100)	6 (100)	2 (100)	9 (82)	9 (90)	4 (50)	12 (86)	70 (78)	47 (80)
Nausea	0 (0)	2 (40)	1 (17)	8 (67)	4 (36)	5 (83)	2 (100)	5 (45)	7 (70)	3 (38)	7 (50)	44 (49)	33 (56)
Vomiting	0 (0)	1 (20)	2 (33)	5 (42)	4 (36)	3 (50)	1 (50)	5 (45)	5 (50)	3 (38)	6 (43)	35 (39)	26 (44)
Fatigue	1 (20)	2 (40)	2 (33)	5 (42)	3 (27)	2 (33)	2 (100)	3 (27)	2 (20)	4 (50)	7 (50)	33 (37)	24 (41)
Decreased appetite	1 (20)	0 (0)	1 (17)	2 (17)	5 (45)	3 (50)	0 (0)	3 (27)	5 (50)	1 (13)	5 (36)	26 (29)	25 (42)



Hyper-glycemia	2 (40)	1 (20)	0 (0)	0 (0)	4 (36)	3 (50)	1 (50)	4 (36)	4 (40)	2 (25)	5 (36)	26 (29)	24 (41)
Maculo-papular rash	1 (20)	2 (40)	1 (17)	3 (25)	3 (27)	3 (50)	2 (100)	3 (27)	1 (10)	1 (13)	4 (29)	24 (27)	15 (25)
Constipation	1 (20)	0 (0)	2 (33)	4 (33)	4 (36)	0 (0)	0 (0)	1 (9)	1 (10)	2 (25)	2 (14)	17 (19)	10 (17)
Abdominal pain	0 (0)	0 (0)	1 (17)	5 (42)	2 (18)	2 (33)	0 (0)	2 (18)	0 (0)	3 (38)	0 (0)	15 (17)	16 (27)
Pyrexia	1 (20)	1 (20)	1 (17)	2 (17)	1 (9)	3 (50)	2 (100)	1 (9)	3 (30)	0 (0)	0 (0)	15 (17)	6 (10)
Headache	0 (0)	1 (20)	1 (17)	2 (17)	1 (9)	1 (17)	0 (0)	2 (18)	1 (10)	0 (0)	0 (0)	9 (10)	15 (25)
Anemia	0 (0)	0 (0)	1 (17)	0 (0)	1 (9)	0 (0)	0 (0)	2 (18)	1 (10)	2 (25)	0 (0)	7 (8)	12 (20)
Increased blood creatinine	0 (0)	1 (20)	0 (0)	1 (8)	3 (27)	0 (0)	0 (0)	0 (0)	0 (0)	1 (13)	0 (0)	6 (7)	10 (17)

Proteinuria	0	0	0	0	1	0	0	0	0	0	0	1	13
	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)	(0)	(0)	(0)	(1)	(22)
Asthenia	0	0	0	0	0	0	0	0	0	0	0	0	12
	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(20)
Hypomag- nesemia	0	0	0	0	0	0	0	0	0	0	0	0	9
	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(15)

## Figure legends

**Figure 1. Multiple-dose PK of AZD5363 (Day 8 of continuous schedule, Day 4 of 4/7, and Day 2 of 2/7 intermittent schedules). A) AUC dosimetry; B) geometric mean ( $\pm$ SD) plasma concentration versus time**

Int, intermittent; SD, standard deviation

**Figure 2. Assessment of PD markers in PRP and paired tumor biopsies following treatment with AZD5363. A) Percentage change from baseline in pThr246 PRAS40 and pSer9 GSK3 $\beta$  markers in PRP at 4 hours post-dose. B) Temporal change in pPRAS40 and pGSK3 $\beta$  in PRP**

In A) and B), percentage change in pPRAS40 and pGSK3 $\beta$  in PRP after a single dose of AZD5363 is shown. Data shown are from Parts A and B only (PD population) and where a result is available for one biomarker or the other. A) Data for each biomarker are ranked in order of descending percentage change and ranking is conducted for each biomarker separately. X indicates missing data. B) Percentage change from baseline in PD markers at various time points after 480 mg single dose (includes all dosing schedules). Samples failing quality control or evaluated as of poor quality, as well as one outlier value for pGSK3 $\beta$  at Cycle 0, Day 3, 0 hours post-dose, were excluded. Horizontal line, median; diamond, mean; box, quartile 1 to quartile 3; whiskers extend from the quartiles to the most extreme observation within 1.5xIQR. Outliers ( $>1.5$ xIQR) are individually displayed. C, cycle; D, day; IQR, interquartile range

**Figure 3. A) Comprehensive assessment of PD activity of AZD5363 in paired tumor biopsies from 12 patients by immunohistochemistry. B) PoM on tumor paired biopsies for pPRAS40 and pGSK3b as proximal indicators of AZD5363 target engagement and therefore selected as the key PoM markers**


A) Total H scores for evaluable pairs are shown for each biomarker (average of 3 non-consecutive tissue sections; details in supplementary material). For Foxo3a/Foxo, the percentage of positive nuclei is shown. Asterisks indicate the patient for whom representative staining images are shown. B)

The percentage change is based on the average H score for individual biomarkers in baseline and on-treatment biopsies from three non-consecutive tissue sections. Each pair of bars represents data from an individual patient; tumor type is indicated in the table (left). X indicates missing data. \**KRAS*-mutant colorectal cancer; †*PIK3CA* E545K mutant cervical cancer (this patient was enrolled in Study 1 Part C). cont, continuous


**Figure 4. Waterfall plots of best percentage change in target lesion size from baseline in patients from A) Parts A and B and B) Part C, with associated molecular data**


A) Exploratory mutation analysis by Sequenom in patients who provided suitable archival tumor tissue, who had baseline tumor assessment, and for whom best percentage change could be calculated. Mutations of potential interest in relationship to modulation of response to AZD5363 or known oncogenic drivers are shown. The *AKT1* mutation detected in one patient was Q43X. B) Progression-free survival (PFS), *PIK3CA*-mutation status by local testing (tissue), central testing (cobas<sup>®</sup> PCR, tissue and plasma), and PTEN status (immunohistochemistry, tissue) are shown. Only patients with baseline tumor assessment and measurable disease and for whom best percentage change could be calculated are included in the plot. The type of tissue used for central and exploratory assessment is indicated (M=metastatic, P=primary). Additional exploratory data on *PIK3CA* and *ESR1* mutations testing in ctDNA by ddPCR are described in Supplementary Table 4 (including time lapse between tissue biopsy and plasma collection) and in the supplementary material

A)




B)







A)



B)



A)



B)

